In 2020, drug spending continued to increase. They amounted to 7.3 billion at the expense of basic insurance, an increase of 4% equivalent to 300 million. However, nearly three quarters of this increase is due to the treatment of cancerous and autoimmune diseases, for which we know that the bill oscillates between 15,000 and 25,000 francs on average per patient and per year. This is where increased use of biosimilars would help curb rising health care costs.
Get the latest news delivered to your inbox
Follow us on social media networks